carbostyril has been researched along with Glomerulonephritis, Lupus in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parikh, SV; Rovin, BH | 1 |
| Hahn, BH; Lourenço, EV; Palma-Diaz, MF; Skaggs, BJ; Wong, M | 1 |
| Furie, R; Toder, K; Zapantis, E | 1 |
| Mok, CC | 1 |
| Furie, R; Narain, S | 1 |
| Clark, MR; Liarski, VM; Trotter, K | 1 |
5 review(s) available for carbostyril and Glomerulonephritis, Lupus
| Article | Year |
|---|---|
Lupus nephritis: the evolving role of novel therapeutics.
Topics: Abatacept; Acute Kidney Injury; Adolescent; Algorithms; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Apoptosis; Autoantibodies; B-Lymphocytes; Cytokine TWEAK; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Humans; Immunoconjugates; Immunosuppressive Agents; Interleukin-6; Lupus Erythematosus, Systemic; Lupus Nephritis; Quinolones; Remission Induction; Rituximab; Tumor Necrosis Factor Inhibitors | 2014 |
Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Boron Compounds; Bortezomib; Clinical Trials as Topic; Drug Discovery; Glycine; Humans; Immunologic Factors; Immunosuppressive Agents; Infliximab; Isoxazoles; Leflunomide; Lupus Nephritis; Mycophenolic Acid; Off-Label Use; Oligonucleotides; Quinolones; Recombinant Fusion Proteins; Rituximab; Tacrolimus; Treatment Outcome | 2015 |
Towards new avenues in the management of lupus glomerulonephritis.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Factors; Biomarkers; Calcineurin Inhibitors; Cyclophosphamide; Cytokine TWEAK; Humans; Immunologic Factors; Lupus Nephritis; Mycophenolic Acid; Precision Medicine; Quinolones; Recombinant Fusion Proteins; Rituximab; Tumor Necrosis Factors | 2016 |
Update on clinical trials in systemic lupus erythematosus.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Clinical Trials as Topic; Cyclosporine; Herpes Zoster; Humans; Immunosuppressive Agents; Interferon Type I; Lupus Erythematosus, Systemic; Lupus Nephritis; Maintenance Chemotherapy; Peptide Fragments; Plasma Cells; Quinolones; Recombinant Fusion Proteins; Remission Induction; T-Lymphocytes; Tacrolimus; Treatment Outcome | 2016 |
Overview of pathophysiology and treatment of human lupus nephritis.
Topics: Abatacept; Antibodies, Monoclonal, Humanized; Autoantibodies; Biopsy; Cyclophosphamide; Dendritic Cells; Disease Progression; Glucocorticoids; Humans; Immunosuppressive Agents; Inflammation; Interferon Type I; Kidney Failure, Chronic; Lupus Nephritis; Maintenance Chemotherapy; Mycophenolic Acid; Prognosis; Quinolones; Recombinant Fusion Proteins; Remission Induction; Ribonucleosides; Severity of Illness Index; T-Lymphocytes, Helper-Inducer; Treatment Outcome; Vimentin | 2016 |
1 other study(ies) available for carbostyril and Glomerulonephritis, Lupus
| Article | Year |
|---|---|
Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells.
Topics: Animals; Disease Models, Animal; Interferon-gamma; Interleukin-10; Interleukin-17; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphocytes; Mice; Myeloid Cells; Quinolones; Tumor Necrosis Factor-alpha | 2014 |